104 related articles for article (PubMed ID: 11890987)
1. Replication status in leukocytes of treated and untreated patients with polycythemia vera and essential thrombocytosis.
Amiel A; Elis A; Maimon O; Ellis M; Herishano Y; Gaber E; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2002 Feb; 133(1):34-8. PubMed ID: 11890987
[TBL] [Abstract][Full Text] [Related]
2. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients.
Herishanu Y; Lishner M; Bomstein Y; Kitay-Cohen Y; Fejgin MD; Gaber E; Amiel A
Cancer Genet Cytogenet; 2001 Jul; 128(2):154-7. PubMed ID: 11463455
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
4. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
5. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea induced skin ulceration in myeloproliferative disorders.
McLintock C; Ockelford PA
Aust N Z J Med; 2000 Jun; 30(3):373-6. PubMed ID: 10914756
[No Abstract] [Full Text] [Related]
7. Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.
Pulik M; Lionnet F; Genet P; Petitdidier C; Jary L; Touahri T
Am J Hematol; 1996 Nov; 53(3):207-8. PubMed ID: 8895700
[No Abstract] [Full Text] [Related]
8. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Gilbert HS
Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
[TBL] [Abstract][Full Text] [Related]
9. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
10. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
Zhang ZR; Duan YC
Asian Pac J Cancer Prev; 2014; 15(4):1681-4. PubMed ID: 24641389
[TBL] [Abstract][Full Text] [Related]
11. How safe is hydroxyurea in the treatment of polycythemia vera?
Haematologica; 1999 Aug; 84(8):673-4. PubMed ID: 10457399
[No Abstract] [Full Text] [Related]
12. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous effects after prolongaded use of hydroxyurea in Polycythemia Vera.
França ER; Teixeira MA; Matias Kde F; Antunes DE; Braz Rde A; Silva CE
An Bras Dermatol; 2011; 86(4):751-4. PubMed ID: 21987143
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea.
Cacciola E; Cacciola RR; Guglielmo P; Stagno F; Giustolisi R
Haematologica; 1999 Aug; 84(8):755-6. PubMed ID: 10457418
[No Abstract] [Full Text] [Related]
15. Other secondary sequelae of treatments for myeloproliferative disorders.
Gilbert HS
Semin Oncol; 2002 Jun; 29(3 Suppl 10):22-7. PubMed ID: 12096354
[TBL] [Abstract][Full Text] [Related]
16. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
Ricksten A; Palmqvist L; Johansson P; Andreasson B
Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
[No Abstract] [Full Text] [Related]
17. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
18. Essential thrombocythemia in a dog: case report and literature review.
Bass MC; Schultze AE
J Am Anim Hosp Assoc; 1998; 34(3):197-203. PubMed ID: 9590446
[TBL] [Abstract][Full Text] [Related]
19. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
20. The optimal management of polycythaemia vera.
McMullin MF; Bareford D; Craig J; Green AR; Harrison C; Oscier DG; Reilly JT;
Br J Haematol; 2003 Feb; 120(3):543-4; author reply 544-5. PubMed ID: 12580978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
